In patients with advanced EGC, the combination of targeted therapy with trastuzumab, cytotoxic chemotherapy (oxaliplatin/cisplatin plus capecitabine/5-FU) and immune checkpoint inhibition (pembrolizumab) was initially investigated in a single-arm phase II trial in 37 patients with Her2-positive metastatic EGC (30% gastric cancer). Here, ERBB2 is linked to gastric cancer.